Tangram Therapeutics submitted a clinical trial application to the U.K. Medicines and Healthcare products Regulatory Agency to initiate a Phase I/II study of TGM‑312 for metabolic dysfunction‑associated steatohepatitis (MASH). The CTA request signals a first‑in‑human step for a candidate targeting a high‑need NASH/MASH population. The planned trial will assess safety, pharmacokinetics and early efficacy signals in patients with metabolic liver disease. Tangram framed TGM‑312 as addressing inflammatory and fibrotic mechanisms of MASH, with the CTA reflecting progression from discovery and translational work toward clinical validation. If authorized, the trial will add another clinical candidate into an increasingly competitive space as companies pursue agents to halt or reverse fibrotic progression in metabolic liver disease.